Showing results (91-100 of 107) with videos related to
Sort By:
Pageof 11
The New England Journal of Medicine|December 8, 2015
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic LeukemiaJan A Burger, Alessandra Tedeschi, Paul M Barr, et al.Nature Medicine|July 21, 2015
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphomaWyndham H Wilson, Ryan M Young, Roland Schmitz, et al.Blood|July 27, 2016
Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphomaAnita Kumar, Carla Casulo, Joachim Yahalom, et al.Blood|December 1, 2020
Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapyAnthony R Mato, Nilanjan Ghosh, Stephen J Schuster, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2021
Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin LymphomaAnita Kumar, Carla Casulo, Ranjana H Advani, et al.Blood|January 12, 2024
Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLLJennifer A Woyach, Gabriela Perez Burbano, Amy S Ruppert, et al.The New England Journal of Medicine|December 4, 2018
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLLJennifer A Woyach, Amy S Ruppert, Nyla A Heerema, et al.American Journal of Hematology|August 23, 2018
Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trialAnthony R Mato, Lindsey E Roeker, John N Allan, et al.The New England Journal of Medicine|June 3, 2014
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemiaJohn C Byrd, Jennifer R Brown, Susan O'Brien, et al.Nature Communications|November 5, 2025
Functional genomics and tumor microenvironment analysis reveal prognostic biological subtypes in Mantle cell lymphomaSunandini Sharma, Roshia Ali, Alyssa Bouska, et al.Pageof 11